An ejection fraction below 35% is generally considered dangerously low. At this level, the heart is pumping out roughly a third or less of the blood in its main pumping chamber with each beat, compared to the 55% or more that a healthy heart ejects. This threshold matters because it’s the point where the risk of life-threatening heart rhythm problems rises sharply, and it’s the cutoff doctors use to decide whether a patient needs a device implanted to prevent sudden cardiac death.
How Ejection Fraction Categories Break Down
Ejection fraction (EF) is simply the percentage of blood your left ventricle pushes out with each heartbeat. A normal EF is 55% or higher in men and 60% or higher in women. The American Heart Association and American College of Cardiology classify heart failure into categories based on this number:
- Preserved EF: 50% or above. The heart squeezes normally, but other problems cause symptoms.
- Mildly reduced EF: 41% to 49%. Pumping power is slightly weakened.
- Reduced EF: 40% or below. This is the formal threshold for heart failure with reduced ejection fraction.
Within that “reduced” category, there’s a meaningful difference between an EF of 38% and one of 20%. The lower the number, the weaker the heart’s pumping ability and the higher the risk of complications. An EF in the teens or single digits represents a heart that is critically failing, and patients at those levels typically have severe symptoms at rest.
Why 35% Is the Critical Line
The 35% threshold comes up repeatedly in cardiology because it’s the level at which the risk of sudden cardiac death from dangerous heart rhythms becomes high enough to justify an implantable cardioverter-defibrillator (ICD). An ICD is a small device placed under the skin that monitors heart rhythm and delivers an electrical shock if it detects a life-threatening arrhythmia. Current guidelines from the ACC and AHA rate ICD implantation as “appropriate” for patients with an EF of 35% or below, whether the cause is a previous heart attack or a non-ischemic condition, as long as the patient is already on optimal medications.
If a patient’s EF improves above 35% with treatment, the case for an ICD weakens. That said, one study following 245 patients who improved past this threshold still found a 20% risk of sudden cardiac death or sustained dangerous arrhythmias over 10 years. So crossing back above 35% lowers risk but doesn’t eliminate it.
What a Dangerously Low EF Feels Like
When the heart can’t pump enough blood to meet the body’s needs, symptoms build gradually or sometimes appear suddenly. Shortness of breath is usually the most prominent, first during physical activity and eventually at rest or while lying flat. Many people notice they need extra pillows to sleep comfortably or wake up gasping at night.
Fluid backs up because the heart can’t move blood forward efficiently. This causes swelling in the ankles, legs, and abdomen, along with rapid weight gain from retained fluid. Fatigue becomes constant and disproportionate to the level of activity. Some people feel lightheaded or dizzy, which can signal that the brain isn’t getting adequate blood flow. At very low ejection fractions, even basic tasks like getting dressed or walking across a room can feel exhausting.
How EF Is Measured, and Why It Matters
Most people first learn their ejection fraction from an echocardiogram, an ultrasound of the heart. It’s noninvasive, widely available, and gives a reasonable estimate. However, echocardiography consistently underestimates ejection fraction. One study comparing it to cardiac MRI (the gold standard for measuring EF) found that echo underestimated EF by about 8 to 10 percentage points on average. Among patients with an EF below 40% on MRI, echo readings averaged 26% while MRI readings averaged 34%.
This gap can change clinical decisions. In that same study, 35% of patients would have been reclassified into a different EF category if cardiac MRI was used instead of echocardiography. If your echo shows a borderline or very low EF, your doctor may order a cardiac MRI for a more precise measurement, especially before deciding on a device like an ICD.
Treatment Can Improve a Low EF
A dangerously low ejection fraction isn’t necessarily permanent. Modern heart failure treatment centers on four types of medications used together, often called the “four pillars.” These include a blood pressure drug that also reduces strain on the heart, a beta-blocker to slow the heart rate and let it fill more effectively, a hormone-blocking medication that prevents fluid retention and scarring, and a diabetes drug (now used in heart failure regardless of diabetes status) that helps the kidneys remove excess fluid and protects the heart. Used in combination, these medications reduce the risk of death and hospitalization, with measurable benefits appearing within days to weeks of starting them.
The priority is getting patients on at least low doses of all four medications as quickly as possible. Many people with heart failure never receive the full combination, which represents a major missed opportunity. When started during a hospital stay, these medications significantly improve survival and reduce the chance of being readmitted.
Some causes of low EF are partially or fully reversible. A heart weakened by a sustained rapid heart rhythm (tachycardia-induced cardiomyopathy) can recover substantially once the rhythm is controlled. Viral infections that inflame the heart muscle, thyroid disorders, and stress-related heart conditions like Takotsubo cardiomyopathy can all cause temporary drops in EF that improve with treatment of the underlying problem. Patients whose EF recovers from 40% or below to above 40% are reclassified as having “improved” ejection fraction, but guidelines recommend they continue taking the same medications, since stopping them risks a decline back to dangerous levels.
Long-Term Outlook
Heart failure with a reduced ejection fraction is a serious diagnosis, but survival has improved meaningfully over the past two decades thanks to better medications and devices. A large study of patients hospitalized with heart failure found that roughly 75% of those with reduced EF survived to five years after adjusting for other health factors. That figure comes from patients treated between 2005 and 2009, before the newest pillar of therapy (the kidney-protective medication) became standard, so current outcomes are likely somewhat better.
The trajectory varies enormously depending on the cause, how well someone responds to medication, and whether they have other conditions like kidney disease or diabetes. Some patients see their EF climb from the low 20s back into normal range. Others stabilize in the 30s and live for years with manageable symptoms. The key variable is how quickly and completely the four-pillar medication regimen is started and whether the underlying cause is treatable.